DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for 2026 that exceeded analyst estimates.

The kidney care provider reported adjusted earnings per share of $3.40 for the fourth quarter, surpassing analyst expectations. Revenue for the quarter rose to $3.62 billion, also beating estimates. The company attributed the strong performance to steady demand for its kidney dialysis services and higher reimbursement rates.

Looking ahead, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the average analyst estimate, signaling strong confidence in future performance. Additionally, the company announced a strategic minority investment in home-care provider Elara Caring to co-develop a kidney-specific home-based care model, which is expected to support growth initiatives in personalized patient care.